everyone call afternoon. you, this and our Thank joining thank to Dan, you
against relates investor some update headwinds peers, I'd many biotech backdrop as has outlook it As the the macro of Like in like on sentiment X, business more our of to position current to Slide the our we of broader the and the environment. space. specifically time the environment turn macro to take regarding the Nabriva you for to faced anti-infective
we're believe the assets our of we to at the market. that parts access As assets, by approximately worth to portfolio credit for sum a we significantly current in undervalued revenue-generating the to than are efficiently that the valuation currently and environment, with challenge. of given clear of it's limited cash result, effectively in be more to see getting our is are With continues raise the currently capital XX% market capital a trading ability market,
have by success and challenges, optionality these effective our primarily as commercial Given we runway cash building is shareholders. most for the value SIVEXTRO shifted extend we to efforts believe way preserve upon our this and and on focus our to efficient
of options, options range on and the maximize value we strategic potential a of advise Additionally, the following of broader Torreya help a with have us business. to underlying Starting Capital assessment engaged to SIVEXTRO.
We September asset, have commercial approximately infrastructure and $XX which year-to-date XXXX. funds of fully net generated through million a sales our revenue-generating has
awareness an patent in asset to potential attributes of future the with has investments of with more value benefits deliver action, we offers monotherapy in and a novel CAP. This a CAP IV is both have approved the for of an an XX life and remaining, to years option and and U.S. XENLETA. of in with the oral that mechanism increase with Second, patients with well-tolerated for drive product XENLETA the
Er-Kim, our U.S. potential China and approval with potential Canada is we untapped the significant income-generating With the in for our appropriate outside partner, separate our Europe partner, the royalty with and resourcing XENLETA has XENLETA also behind believe Sunovion, the in distinct with in opportunities there potential the with with brand, in U.S. X Sumitomo. Eastern partner,
to with life another Additionally, cystic million $XXX treatment incremental patients in in XENLETA generate of opportunity up with potential the sales. peak could management cycle have fibrosis we that
the top in having the XENLETA forward data cystic Given population, and end to before fibrosis concentrated optimistic patient look of remain line potential we the of about small this year.
mechanism treating Lastly, while efficient attempt through currently in from multidrug-resistant near to the on indications. in verge generating To this value growing have patients over a for of assets track assets patent XXXX, action, novel generating believe treatment With X near our with U.S. with and organisms product million full the summarize, potentially future. U.S. or for across United MDRs, treat a record and for the look the path they patients both to over shareholders. most of of we an as assets attractive optionality these this multiple and to revenue our States. exclusivity CONTEPO, maintaining the term, in is value maximize have years, the of runway forward in CONTEPO with extending now we cash extended a provides proven the we With our U.S., various for outside issue we the XX the alternative the backdrop, realize
Moving like to to made of cash efforts to some Slide the position. we've our highlight optimize I'd X.
projects reorganizing back-office all support. and in and XX% our functions includes reduction implementing global streamlining noncore R&D a strategy Our suspending workforce by
end of result, operating have remove approximately operating XXXX. our XXXX. of reduced expenses base These operating business, we extended expenses, a our cash runway the the created by the into As of first XX% efforts plan within efficiencies and from quarter will
controlling is position, business our Our believe upon and existing a We adequately can optimize time building us near-term within commercial assess our while value what to cash portfolio maximize our from business. individual assets shareholder value-creating we across provides of this enhance execution. our broader range to value, control the focus efficiently by within options
X. to Slide Moving
execution our operational We be by the encouraged in business. continue to
with XXXX previous I'm on the we the a middle on continued in with thrilled We quarter-on-quarter of our continue momentum the line run acceleration demand. the SIVEXTRO. capitalizing to On the XX% we our achieved of demand SIVEXTRO, commercial and in hitting sales had the significant peak have that in goal TRx execution growth force side, acceleration in saw sales guidance. focus historical rate of
mentioned, we improvements see strategic a the we plan I in efforts cash year. value burn our cash restructuring operating and to to have our reduce refocus continue prior to implemented burn drivers, compared on near-term As and
We disciplined the ourselves of continue leverage by challenge operating continued to further SIVEXTRO. driven be to growth accelerate with the to spending
demonstrated expect of to side data execute side, On now Phase from acceleration we ability top I This operationally as the from study XXXX. This the the in an we line XXXX. guidance the is clinical cystic a of business. to QX is our fibrosis previous in the team clinical have the credit QX
the points the this We in of have possibilities will later and population, presentation. XENLETA in patient previously I about reiterate talked these
on lefamulin remains expected regulatory NDA approval China track of with decision half an the in the second Lastly, XXXX.
million will generate potential milestones. in As has recall, up this incremental to and sales double-digit royalties regulatory and you to the $XX low
Another within opportunity value over significant portfolio the the next creation months. XX
consecutive prescription As demand 'XX its in demand XXXX. prescription XX% growth of year-to-date X-month period QX you growth the can versus QX double-digit same compared SIVEXTRO see with demand 'XX on third quarter posted prescription to of Slide X, growth XX% and
quarter, the prescriptions. generating saw prescription During X,XXX another promotion demand the we restarted recent yet retail since of high retail we brand, in
our is objectives of to our April with example were with have back foundational footprint. confidence in retail commercial SIVEXTRO to On in grow of getting This operationally another ability achieved demand, momentum on in SIVEXTRO's rate historical of in the confident of implemented efforts SIVEXTRO this remain to of year. guidance XXXX. asset reaffirms we the promotion continued run portfolio. our as sales realignment by continue that and peak solid view of ability this to prescription our The We goals the the and deliver middle this a our back our
move third compared call are of the for realignment quarter April we of of doubled XXXX encouraged Slide to this on first our SIVEXTRO that quarter the As reach more following year. see has X, in than to XXXX we our to in target
SIVEXTRO writers realignment, opportunity new the of continue the since within for is podiatrists the promotionally expand of written. with and nature XX% this of XXX prescriptions the to we SIVEXTRO's those segment brand prescribers. converted given to accounting use have encouraging Additionally, key This sensitive new
it key continue with to expand to their the to nature This MRSA as We we The we demonstrated the that we commercial brand. activity, of sensitive around aureus increased treatments momentum has XENLETA believe I Because our Shifting combining is in identify rationale staphylococcus in our thesis against CF focus both Foundation promotionally exploring in up continued and forward XENLETA MRSA. expect reach to established well of CF Staph sets for SIVEXTRO, that frequency cystic and IV anti-inflammatory is -- focus a penetration, methicillin-resistant reach patients tolerated. with with this on with staph areas formulation, an move and one medical chronic expect XENLETA with trial for evaluating fibrosis, lung when patients anti-MRSA fibrosis. aureus patients focus to the Phase supports of of Slide has need an as out option our CF our aureus stated an update of potent infections. patients treatment remains is XENLETA available activity, and strategy lays XX excellent oral unmet cystic and potent effective for
believe an this difficult-to-treat We may treatment population. continue provide that to attractive for option
the cystic CF We a I forward that positive our XENLETA partnership data top in now quarter. sharing for in revenue the prior trial XXXX, over another in $XXX financials important catalyst opportunity potential I'd completed XXXX. now QX turn weeks for line the could million. believe the and with patient potential with Dan data data presentation the for guidance in of in peak look have this months enrollment Foundation on We with study to market of fibrosis in incremental ahead. the the create and a to QX third to We these Phase update brief accelerating this population expect like
